Once a drug target is identified, it often takes decades until a chemical compound is developed that can hit the bullseye and become a useful medicine. To speed up the process, Zheng is using a recent ...

Chemoproteomics screening platform identified novel covalent inhibitors that specifically disrupt RAS-mediated activation of the catalytic subunit of PI 3-kinase alpha (PI3Kα) Newly identified group ...

Novartis is serving up $60 million to partner with Matchpoint Therapeutics in hopes of getting an oral covalent inhibitor over the line for inflammatory diseases that have been historically difficult ...

Scientists at the University of Birmingham have developed a new class of MRI contrast agents, improving their stability to ...

Vertex Pharmaceuticals is offering Enlaza Therapeutics more than $2 billion in biobucks through a multitarget drug discovery deal aiming to create new T-cell engagers and small-format drug conjugates.